<sec><title>Objective</title>To assess the prevalence and the profile of adverse events (AE) of natalizumab in patients with multiple sclerosis (MS).</sec><sec><title>Methods</title>Data collection from neurologists attending to patients with MS at specializ...
Similar Items
-
by: Yára Dadalti Fragoso, et al.
Published: (2013-03-01) -
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive
by: Yara Dadalti Fragoso, et al.
Published: (2013-10-01) -
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
by: Yara Dadalti Fragoso, et al.
Published: (2016-08-01) -
Evolução favorável de recidiva de infecção por varicela zoster (cobreiro) durante uso de natalizumabe em paciente com esclerose múltipla: relato de caso
by: Diego Rafhael Soares Carvalho Feitosa, et al.
Published: (2017-04-01) -
Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
by: Enedina Maria Lobato de Oliveira, et al.
Published: (2015-09-01)